Novo Nordisk Loses Brazil Share as Generics Pressure Emerging-Market Sales
CEO Mike Doustdar told Reuters that Novo Nordisk’s market share is falling in Brazil after its semaglutide patent expired, contributing to a 3% decline in third-quarter emerging-market sales. The company largely held its ground in Canada and India.
By Jacob Gronholt-Pedersen and Patrick WingroveNovo Nordisk is losing market share in Brazil after its semaglutide patent expired, driving a 3% decline in emerging market sales in the third quarter, CEO Mike Doustdar told Reuters, while the drugmaker has largely held its ground in Canada and India…